Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$967.98 10.23 (1.05%) as of 4:30 Thu 5/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 101.34(B)
Last Volume: 407,580 Avg Vol: 767,398
52 Week Range: $692.45 - $993.35
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 14,295 77,700 120,701 282,978
Total Sell Value $13,799,540 $71,512,799 $107,160,703 $220,505,683
Total People Sold 6 13 15 17
Total Sell Transactions 13 37 55 116
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 2410
  Page 18 of 97  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bassler Bonnie L Director   –       •      –    2022-01-03 4 A $0.00 $0 D/D 191 1,082     -
   Yancopoulos George President and Chief Scientific   •       •      –    2021-12-22 4 D $610.04 $189,171,574 D/D (310,097) 1,019,653     -
   Yancopoulos George President and Chief Scientific   •       •      –    2021-12-22 4 OE $179.13 $97,775,813 D/D 442,267 1,169,835     -
   Vagelos P Roy Director   –       •      –    2021-12-16 4 D $634.70 $80,008 I/I (126) 2,095     -
   Landry Robert E EVP Finance CFO   •       –      –    2021-12-13 4 AS $662.50 $76,850 D/D (116) 29,260 5%     
   Mccourt Marion EVP Commercial   •       –      –    2021-12-13 4 AS $653.12 $224,673 D/D (344) 19,644 5%     
   Larosa Joseph J EVP General Counsel and Secret   •       –      –    2021-12-11 4 D $664.34 $463,045 D/D (697) 26,051     -
   Van Plew Daniel P EVP & General Mgr, Industrial   •       –      –    2021-12-11 4 D $664.34 $463,045 D/D (697) 30,578     -
   Murphy Andrew J EVP Research   •       –      –    2021-12-11 4 D $664.34 $463,045 D/D (697) 58,470     -
   Landry Robert E EVP Finance CFO   •       –      –    2021-12-11 4 D $664.34 $463,045 D/D (697) 29,376     -
   Mccourt Marion EVP Commercial   •       –      –    2021-12-11 4 D $664.34 $257,764 D/D (388) 19,988     -
   Fenimore Christopher R. SVP Controller   •       –      –    2021-12-11 4 D $664.34 $179,372 D/D (270) 21,122     -
   Stahl Neil EVP Research and Development   •       –      –    2021-12-11 4 D $664.34 $500,248 D/D (753) 53,130     -
   Landry Robert E EVP Finance CFO   •       –      –    2021-12-10 4 D $664.34 $919,447 D/D (1,384) 30,073     -
   Landry Robert E EVP Finance CFO   •       –      –    2021-12-10 4 OE $555.67 $833,505 D/D 1,500 31,457     -
   Landry Robert E EVP Finance CFO   •       –      –    2021-12-10 4 AS $656.46 $520,477 D/D (781) 29,957 3%     
   Murphy Andrew J EVP Research   •       –      –    2021-12-10 4 AS $657.61 $4,745,202 D/D (7,122) 59,167 3%     
   Tessier-Lavigne Marc Director   –       •      –    2021-12-09 4 AS $665.00 $2,516,360 D/D (3,784) 2,078 6%     
   Tessier-Lavigne Marc Director   –       •      –    2021-12-09 4 OE $371.40 $1,405,378 D/D 3,784 5,862     -
   Landry Robert E EVP Finance CFO   •       –      –    2021-12-09 4 D $657.11 $2,279,515 D/D (3,469) 30,738     -
   Landry Robert E EVP Finance CFO   •       –      –    2021-12-09 4 OE $399.66 $1,698,555 D/D 4,250 34,207     -
   Larosa Joseph J EVP General Counsel and Secret   •       –      –    2021-12-09 4 D $657.11 $12,992,379 D/D (19,772) 26,748     -
   Larosa Joseph J EVP General Counsel and Secret   •       –      –    2021-12-09 4 OE $179.13 $5,373,900 D/D 30,000 46,520     -
   Murphy Andrew J EVP Research   •       –      –    2021-12-09 4 D $657.11 $6,162,378 D/D (9,378) 66,289     -
   Murphy Andrew J EVP Research   •       –      –    2021-12-09 4 OE $52.03 $858,495 D/D 16,500 75,667     -
  2410 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 18 of 97
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us